MAIA Biotechnology Announces Progress in THIO-101 Phase 2 Trial

MAIA Biotechnology, Inc. reported on October 27, 2025, that it presented a trial in progress poster at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. The company also announced the enrollment of five patients from Taiwan and Turkey in the expansion phase of its THIO-101 Phase 2 trial. The trial evaluates the safety and efficacy of ateganosine (THIO) in combination with immune checkpoint inhibitors for patients with advanced non-small cell lung cancer (NSCLC) who have developed resistance to prior treatments. The company highlighted the potential of ateganosine as a promising treatment option for NSCLC, particularly in regions with high prevalence of lung cancer. The trial is ongoing in multiple locations across Europe and Asia, aiming to expand patient access and gather more data on the treatment's effectiveness.